Research Article
No access
Published Online: 16 December 2020

Nationwide Shortage of Albuterol Inhalers and Off-Label Use in COVID-19 Patients

Publication: Pediatric Allergy, Immunology, and Pulmonology
Volume 33, Issue Number 4


The surge in COVID-19 cases during the 2020 Spring led to a nationwide shortage of albuterol inhalers. As a new surge has begun, shortages may make it difficult for patients with obstructive lung disease, including children with asthma, to obtain refills. Since there is no evidence that albuterol relieves symptoms in COVID-19 patients with respiratory symptoms not caused by bronchospasm, it is reasonable for clinicians to not prescribe it for COVID-19 patients unless they also have asthma or chronic obstructive pulmonary disease.

Get full access to this article

View all available purchase options and get full access to this article.


1. American Society of Health-System Pharmacists. Drug shortage list. 2020. Available at: (accessed November 29, 2020).
2. New York City COVID-19 Tracking Project. Hospital Admissions for COVID-19, March 15–30, 2020. Available at: (accessed October 21, 2020).
3. Premier, Inc. Data shows drugs essential to providing care for COVID-19 patients quickly slipping into shortage. Available at: (accessed October 21, 2020).
5. FDA. FDA approves first generic of ProAir HFA. Available at: (accessed October 21/2020).
6. FDA. Search list of extended use dates to assist with drug shortages. Available at: (accessed October 18/2020).
7. Lupin. Lupin receives approval for generic albuterol sulphate MDI. Available at: (accessed October 21, 2020).
8. Generics Bulletin. FDA reveals scale of perrigo albuterol problem. Available at: (accessed October 21, 2020).
9. American Thoracic Society. SARS-CoV-2 transmission and the risk of aerosol-generating procedures. Am J Respir Crit Care Med 2020;202:13–14.
10. Tang JW, Kalliomaki P, Varila TM, et al. Nebulisers as a potential source of airborne virus. J Infect 2020;81:650–652.
11. ElMallah MK, Hendeles L. Delivery of medications by metered dose inhaler through a chamber/mask to young children with asthma. Pediatr Allergy Immunol Pulmonol 2012;25:236–240.
12. Grasselli G, Tonetti T, Protti A, et al. Pathophysiology of COVID-19-associated acute respiratory distress syndrome: a multicentre prospective observational study. Lancet 2020:
13. Perkins GD, McAuley DF, Thickett DR, et al. The beta-agonist lung injury trial (BALT1); a randomized Placebo-controlled clinical trial. Am J Respir Crit Care Med 2006;173:281–287.
14. The National Heart, Lung and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network. Randomized placebo-controlled clinical trial of an aerosolized beta2-agonist for treatment of acute lung injury. Am J Respir Crit Care Med 2011;184:561–568.
15. Smith FG, Perkins GD, Gates S, et al. Effect of intravenous beta-2 agonist treatment on clinical outcomes in acute respiratory distress syndrome (BALTI-2): a multicentre, randomised controlled trial. Lancet 2012;379:229–235.
16. Perkins GD, Gates S, Park D, et al. The beta agonist lung injury trial prevention. A randomized controlled trial. Am J Resp Crit Care Med 2014;189:674–683.
17. Budinger GRS, Mutlu GM. Beta-2 agonists and acute respiratory distress syndrome. Am J Resp Crit Care Med 2014;189:624–625.
18. Claesson J, Freundlich M, Gunnarsson I, et al. Scandinavian clinical practice guideline on fluid and drug therapy in adults with acute respiratory distress syndrome. Acta Anaesthesiol Scand 2016;60:697–709.
19. Halpin DMG, Faner R, Sibila O, et al. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? (Comment). Lancet Respir Med 2020;8:436–448.
20. Hendeles L, Marshik PL, Ahrens R, et al. Response to nonprescription epinephrine inhaler during nocturnal asthma. Ann Allergy Asthma Immunol 2005;95:530–534.
21. Blake K, Raissy H. Nonprescription epinephrine metered-dose inhaler: to be or not to be. Ped Allergy Immunol Pulm 2014;27:143–146.

Information & Authors


Published In

cover image Pediatric Allergy, Immunology, and Pulmonology
Pediatric Allergy, Immunology, and Pulmonology
Volume 33Issue Number 4December 2020
Pages: 216 - 219
PubMed: 35921564


Published online: 16 December 2020
Accepted: 3 December 2020
Published in print: December 2020
Received: 24 October 2020


Request permissions for this article.




Leslie Hendeles [email protected]
College of Pharmacy and University of Florida, Gainesville, Florida, USA.
Department of Pediatrics, University of Florida, Gainesville, Florida, USA.
Sreekala Prabhakaran
Department of Pediatrics, University of Florida, Gainesville, Florida, USA.


Address correspondence to: Leslie Hendeles, PharmD, 3549 NW 30th Blvd., Gainesville, FL 32605, USA [email protected]

Author Disclosure Statement

Dr. Hendeles has been a consultant to Aurobindo, Cipla, and Lupin companies developing generic albuterol inhalers and to Amphastar, manufacturer of epinephrine inhaler. Dr. Prabhakaran has nothing to disclose.

Funding Information

No funding was received.

Metrics & Citations



Export citation

Select the format you want to export the citations of this publication.

View Options

Get Access

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.

Society Access

If you are a member of a society that has access to this content please log in via your society website and then return to this publication.

Restore your content access

Enter your email address to restore your content access:

Note: This functionality works only for purchases done as a guest. If you already have an account, log in to access the content to which you are entitled.

View options


View PDF/ePub

Full Text

View Full Text







Copy the content Link

Share on social media

Back to Top